This site is intended for U.S. healthcare professionals.

Mechanism of Action

BASED ON PRECLINICAL TRIALS

ONUREG® is an oral HMA that induced cell apoptosis, decreased tumor burden, and increased survival in leukemic models1

ONUREG® is incorporated into both DNA and RNA where it exerts multiple antileukemic effects1

ONUREG® MOA Graphic ONUREG® MOA Graphic
  • Incorporation of ONUREG® into DNA allowed for inhibition of DNA methyltransferases, reduction of DNA methylation, and alteration of gene expression, including re-expression of genes regulating tumor suppression and cell differentiation
  • Incorporation of ONUREG® into RNA inhibited RNA methyltransferases, reduced RNA methylation, decreased RNA stability, and decreased protein synthesis

HMA, hypomethylating agent.

Pharmacodynamic profile for ONUREG®1

  • Greater reduction in global DNA methylation was observed with higher azacitidine plasma exposure in patients with AML administered ONUREG® for 14 days of a 28-day treatment cycle

Recommended dosing1

Oral 14-day dosing of ONUREG® allows for extended drug exposure during each treatment cycle to prolong therapeutic activity
  • The recommended dosage of ONUREG® is one 300 mg tablet orally, once daily for 14 days of a 28-day treatment cycle

This site is best viewed in portrait mode on a smartphone or small tablet.